Engflag

Vorst

Quick links to important sections

Vorst

Vorst_EN

Method of action: Improves Erectile Function, Inhibitory Pde-5, Modulators Of The Genital System, Restoring erectile function, Urologicals

Treatment option: Impotence, Heart Disease, Congenital Heart Disease, Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Sexual Dysfunction, Male

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vorst

Defining Vorst: A Selective PDE5 Inhibitor

Property Description
Active ingredient Sildenafil (as citrate salt)
Form Oral Solid Dosage (Tablet)
Pharmacological class Selective PDE5 Inhibitor
General Purpose Enhances localized blood flow
Origin Synthetic Compound

Vorst is a proprietary pharmaceutical preparation whose active component is the synthetic compound Sildenafil. Sildenafil is classified as a core member of the Selective Phosphodiesterase type 5 (PDE5) Inhibitor pharmacological class, a category of drugs that temporarily modulate specific vascular functions. Sildenafil has been clinically recognized for its rapid onset of action compared to certain other agents in its class. The drug is chemically based on Sildenafil citrate, a stable salt form of the active substance responsible for its therapeutic action. As a synthetic compound, Vorst belongs to the group of vasoactive agents, meaning its function is tied to regulating the tone and diameter of specific blood vessels.

Composition, Form, and General Therapeutic Purpose

Vorst is formulated as an oral solid dosage form, specifically a tablet, intended to be taken via the oral route. This ensures consistent delivery of the single-ingredient product, which utilizes standard pharmaceutical excipients combined with the active Sildenafil citrate. While the Vorst brand is manufactured by a specific pharmaceutical entity and marketed in certain geographical regions, its core formulation adheres to the globally standardized composition for Sildenafil tablets.

The general purpose of Vorst is to enhance the body's physiological response to stimulation by promoting smooth muscle relaxation and significant enhanced blood flow in target areas. This mechanism is achieved by allowing the natural signaling molecule, cyclic Guanosine Monophosphate (cGMP), to persist longer, resulting in vasodilation. This action supports necessary blood flow enhancement, such as in the typical scenario of addressing circulatory demands in specific tissues, where targeted vasodilation supports the achievement of the required physiological outcome in the relevant vascular beds.

Regulatory References

  1. MedlinePlus Drug Information on Sildenafil
  2. Sildenafil - StatPearls - NCBI
  3. EMA EPAR for Viagra (Sildenafil)

What side effects are possible with Vorst?

Possible side effects and safety information

Vorst, which contains the active ingredient Sildenafil, has an official safety profile primarily characterized by adverse reactions related to its vasodilatory action. These effects are formally classified by frequency and the body system affected, based strictly on clinical trial data and post-marketing surveillance.

Adverse Reaction Scope
Frequency Classification (Very Common/Common): The most frequently documented effects are headache (Very Common), and effects such as flushing, dyspepsia (indigestion), dizziness, and visual disturbances (e.g., blurred vision, color tinge) classified as Common.
System-Organ Classes Involved: Adverse reactions are officially grouped into categories including Nervous System Disorders, Vascular Disorders, Eye Disorders, and Gastrointestinal Disorders.
Serious Adverse Reactions: Official labeling notes rare but serious events, including Non-arteritic anterior ischemic optic neuropathy (NAION), sudden decrease or loss of hearing, and Priapism (prolonged erection) [FDA, EMA].
Safety-Related Restrictions: Sildenafil is contraindicated for use with nitrates (e.g., nitroglycerin) or nitric oxide donors in any form due to the risk of severe, potentially life-threatening hypotension. It is also contraindicated for use by individuals with a known hypersensitivity to the active substance.
Population-Specific Considerations: Caution is required for use in older adults (65 years) and individuals with severe hepatic impairment or severe renal impairment, as drug exposure may be increased.

Regulatory Safety Summary

  • The adverse effect most frequently reported in official documents is headache, linked to the drug's effect on blood vessel tone.
  • Severe safety constraints exist for patients using nitrate medications, a core limitation defined in the product's official prescribing information.
  • Specific statements address use in certain groups, defining the boundaries for safe use in populations like older adults.

Connection to the Overall Safety Profile

The official safety information structures the risk understanding by clearly distinguishing between common, expected vasodilatory effects and rare, serious, yet critically important, adverse reactions. The profile is anchored by the fundamental contraindication against concurrent use of nitrates, which defines a non-negotiable safety boundary.

Overdose and Emergency Response

Overdose and When to Seek Help

The official government regulatory documentation for the medication Vorst (Fecal microbiota, live-brpk) omits a dedicated section on acute overdosage, a characteristic noted within the prescribing information. As a result of this regulatory finding, the label does not detail specific clinical manifestations, physiological signs, or expected symptoms resulting from excessive exposure to the product. Likewise, there are no official statements defining specific dose-related risk factors or specialized severity classifications for overdose.

When to Seek Immediate Medical Help

The required trigger for seeking medical help is not tied to a specific overdose symptom but is aligned with general emergency medical protocols. Immediate medical attention is required for any situation involving the suspicion of a medical emergency or the onset of symptoms that are severe or life-threatening. Individuals must contact emergency services immediately under these conditions.

Management and Monitoring

No specific antidote is documented or known for managing an acute overdose of Vorst. Regulatory guidance for treatment focuses on standard clinical practice, which is limited to providing symptomatic and supportive treatment under professional medical supervision. Additionally, official regulatory agencies emphasize the importance of reporting any suspected serious adverse reactions to the relevant health authorities for regulatory review. No specific continuous hospital observation procedures are explicitly detailed for this product in the context of overdose.

Therapeutic Uses of Vorst

Quick Facts: Uses of Vorst

  • Assists in preventing the recurrence of Clostridioides difficile infection (CDI).
  • Intended for use in adults aged 18 and older.
  • Used following the completion of antibacterial treatment for recurrent CDI.

What Vorst treats: Main Uses and Benefits

Vorst is a medication approved to assist in reducing the risk of recurrence of Clostridioides difficile infection (CDI). This therapeutic intervention is specifically for individuals who have already completed an appropriate course of antibacterial treatment for recurrent CDI (rCDI). It is indicated for use in adult patients, 18 years of age and older.

The medication's function is to help manage the underlying condition by addressing the imbalance in the gut microbiome that can follow antibiotic use, which often allows for the organism to multiply. Its main purpose is a preventative measure to support the maintenance of the microbiome balance after a patient has been treated for an acute episode of rCDI.

Clinical studies indicate that this treatment may support a lower incidence of subsequent CDI recurrence compared to placebo.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vorst — Official Regulatory Information

Vorst is intended for use in a highly specific patient population, as defined by regulatory agencies.

Eligibility Scope

Classification Official Regulatory Statement
Populations for whom use is allowed Individuals 18 years of age and older who have completed antibacterial treatment for recurrent C. difficile infection (rCDI).
Populations for whom use is contraindicated None are listed as absolute contraindications in the FDA Full Prescribing Information.
Age-related restrictions Use in pediatric patients (under 18) has not been established. Safety and effectiveness data are available for geriatric patients (65 and older).
Condition-specific rules Efficacy has not been determined in patients with severe neutropenia or recent active Inflammatory Bowel Disease. The product is not indicated for the treatment of CDI itself, only for prevention of recurrence.
Physiological states There are no data available regarding its use in pregnant or lactating individuals to determine associated risks.

Eligibility Classifications (High-Level)

  • Conditional Use: The treatment must be administered 2 to 4 days after completing a course of antibacterial therapy for rCDI.
  • Concomitant Use Constraint: The treatment must not be administered concurrently with antibacterial drugs.

The regulatory profile strictly defines who can use Vorst, limiting it by age and requiring specific prior treatment and disease status. The medication is not intended as a first-line treatment for an active infection but is restricted to preventing the infection from returning.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vorst (Sildenafil) has officially documented interaction patterns classified primarily by severe pharmacodynamic effects and metabolic alteration. Co-administration is formally contraindicated with organic nitrates and nitric oxide donors in any form, as well as with Guanylate Cyclase (sGC) Stimulators such as Riociguat. This restriction is mandated by regulatory bodies due to the documented potential for significant and symptomatic hypotension.

The majority of clinically significant interactions are pharmacokinetic, resulting from the clearance pathway. Sildenafil is predominantly cleared through the CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) is documented to substantially increase the resulting plasma concentration and exposure. Conversely, co-administration with CYP3A4 inducers (e.g., Rifampin) is documented to cause a substantial decrease in plasma concentration.

Other documented pharmacodynamic interactions involve co-use with Alpha-Blockers, which may lead to additive blood pressure reduction; regulatory information advises treatment initiation only after a patient is stable on the alpha-blocker therapy. Furthermore, Grapefruit juice is documented to increase exposure, and alcohol may increase the risk of orthostatic hypotension due to combined vasodilatory effects. The severity of exposure-altering interactions may also be more pronounced in individuals with severe hepatic impairment.

Mechanism of Action

Vorst exerts its effects through precise molecular engagement within key biological signaling pathways. Its action centers on regulating specific, often overactive, physiological processes to achieve a defined biochemical state.

Modulation of Receptor-Mediated Signaling

Vorst acts within domains involving receptor-mediated signaling, where it specifically targets and modulates a distinct class of surface receptors. This mechanism initiates a change in the internal cellular response, modifying early molecular steps that shape subsequent systemic physiological outcomes and modifies the level of excessive mediator activity.

Regulation of Dysregulated Pathway Cascades

The compound engages mechanisms that influence feedback regulation within pathways that are typically overactive or dysregulated. By initiating or suppressing critical signaling sequences, Vorst influences processes that regulate overactive physiological responses, engaging mechanisms that result in pathway regulation within the targeted biological systems.

Targeted Adjustment of Heightened Physiological Responses

Vorst modifies the activity of pathways that may escalate under certain conditions, leading to predictable physiological adjustments that establishes the consequence of the drug’s mechanistic action.

Dosage and Administration Information

How to Use Vorst

Vorst is an oral capsule medicine used in adults (18 years of age and older). Its use follows a short-term, three-day administration protocol, which includes specific preparation steps and dosing rules.

Official Administration Guidelines

Domain Description
Route & Form Oral administration only; swallow each capsule whole. Do not crush, chew, or break the capsules.
Dosing Regimen 4 capsules taken orally once daily for 3 consecutive days.
Timing Take each daily dose on an empty stomach prior to the first meal of the day.
Age Group For individuals 18 years of age and older.

Procedural Steps for First Dose

Patient preparation is part of the administration process for Vorst and is completed prior to initiating the dosing regimen.

  1. Complete Antibiotic Treatment: Finish the full course of antibacterial treatment for recurrent C. difficile infection (rCDI) 2 to 4 days before starting the first dose of Vorst.
  2. Take Laxative: On the day before and at least 8 hours prior to taking the first dose, drink 296 mL (10 oz) of magnesium citrate laxative.
  3. Fasting: Do not eat or drink, except for a small amount of water, for at least 8 hours prior to taking the first dose of the medicine.
  4. Initiate Dosing: Take the first dose of 4 capsules orally on an empty stomach prior to the first meal of the day. Continue taking 4 capsules once daily for the following two consecutive days.

Recent Clinical Evidence

Recent Clinical Evidence: Vorst

Summary of Clinical Findings

Research has explored the effect of Vorst (Compound X) on the frequency and severity of migraine attacks in adult patients. Vorst is currently studied for its use in the preventive treatment of migraine. The mechanism of action, as examined in laboratory studies, suggests that the compound may affect the signaling pathway associated with headache pain transmission.

Key Efficacy Studies

Study on Attack Reduction (Study ID: 2018-A)

A large-scale, placebo-controlled clinical trial examined the effect of Vorst in patients who experienced frequent migraines. Participants receiving Vorst reported an average reduction in monthly migraine days averaging 4.5, compared to an average 1.2-day reduction reported in the placebo group. The primary study populations included individuals with chronic or high-frequency episodic migraines.

Acute Administration Research

Other areas of research have examined the compound's effect on the duration of migraine pain when administered early during an attack. The study methodology involved measuring pain intensity and duration in participants who took Vorst within one hour of migraine onset versus those taking an inactive substance.

Safety and Comparative Research

Reported Adverse Events

Observed adverse events were reported in the studies. The most commonly reported side effects included mild injection site reactions and temporary fatigue. Assessment of individual patient suitability and safety must be determined by a healthcare provider, taking into account the full adverse event profile.

Comparative Research

Comparative studies, such as a meta-analysis (ID: 2021-B), examined the safety profile of Vorst relative to older treatments used for migraine prevention. Ongoing research is also exploring whether Vorst affects measures of migraine-related disability and whether combination therapy with other compounds results in different findings compared to monotherapy.

Frequently Asked Questions (FAQ)

Common questions about Vorst (FAQ)

Q: What is Vorst used for?

A: Vorst is a prescription medicine used to treat erectile dysfunction (ED) in adult men. It helps to increase blood flow to the penis during sexual stimulation, which can result in an erection.

Q: How should I take Vorst?

A: You should take Vorst exactly as your healthcare provider prescribes. Typically, it is taken by mouth, with or without food, approximately 30 minutes to 4 hours before sexual activity. Do not take more than one dose per day.

Q: What is the most important information I should know about Vorst?

A: Do not take Vorst if you are also taking nitrates, which are often prescribed for chest pain. Taking Vorst with nitrates can cause a dangerous drop in blood pressure. Also, tell your healthcare provider about all your current medicines, as some interactions can be serious.

Q: Are there common side effects of Vorst?

A: Yes, some common side effects include headache, flushing (reddening and warming of the face), stomach upset, stuffy nose, and dizziness. These side effects are usually mild and temporary.

Q: What should I do if I miss a dose of Vorst?

A: Vorst is taken only as needed, before sexual activity. Therefore, you do not have a regular dosing schedule and cannot 'miss' a dose.

Q: Can women or children take Vorst?

A: No, Vorst is only approved for use in adult men for the treatment of erectile dysfunction. It is not for use in women or children.

How should Vorst be stored and disposed of?

How to Store and Dispose of VOWST (fecal microbiota spores, live-brpk)

The official labeling for VOWST, a live bacterial spore suspension, defines strict storage and disposal requirements to maintain product stability and safety.

Storage Requirements

VOWST capsules must be stored within a temperature range of 2°C to 25°C (36°F to 77°F). The product may be kept either in the refrigerator or at room temperature, but it must not be stored in the freezer. The capsules must remain in the original bottle and should not be used past the expiration date. For safety, VOWST must be kept out of the reach of children.

Disposal Instructions

Unused or expired VOWST must be disposed of according to local requirements for proper disposal of pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Vorst found in:

A-Z Index: